Biotech News
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced positive data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody, from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting of the American College of Rheumatology.
